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Breast cancer is a leading type of cancer among women in India as well as worldwide. 
According to the WHO 2015 report, it has been anticipated that there would be a twofold 
rise in the death due to breast cancer among women. The heterogeneous property of 
breast carcinoma has been suggested to be linked with dedicated set of communication 
and signaling pathway with their surroundings, which culminate into progression and 
development of the cancer. Among the plethora of communication tools in the hand of 
breast carcinoma cells is the recently appreciated exocytosis of the tightly packed short 
non-coding RNA molecules, predominantly the microRNAs (miRNAs). Recent studies 
suggest that miRNAs may work as courier messengers to participate in endocrine and 
paracrine signaling to facilitate information transfer between breast carcinoma and their 
neighboring cells. Evidence suggests that breast tumor cells communicate via packaged 
miRNAs in the tumor-released microvesicles, which enrich the tumor microenvironment. 
There is a strong view that dissecting out the mechanistic and regulatory aspects of 
miRNA export and role may uncover many prospects for overcoming the signaling 
defects and thereby controlling aberrant cell division. The detection of circulating miRNAs 
associated with breast carcinoma can also be used as biomarkers for early diagnosis. 
This review article is an attempt to provide updated knowledge on implications of short 
RNAs and their transport in the breast cancer pathophysiology.
Keywords: non-coding short RNA, microRNA, breast tumor, signaling, extracellular vesicles, targeting, breast 
carcinoma
iNTRODUCTiON
According to the WHO World Cancer Report 2015, there are about 14 million newly diagnosed 
and 8.2 million cancer-related mortality cases worldwide (1). Among several types of cancer, breast 
cancer is the most noticeable carcinoma among women in developed and developing countries, 
where estimated cases until 2012 were 1.7 million that resulted in 521,900 deaths, accounting 
for 25% of all cancer cases and 15% death in females (1–3). The bottleneck to surmount breast 
cancer lies in drugs/inhibitors resistance, aberrant signaling, appetite to continuously grow, and 
manipulated communication skills among the breast carcinoma cells (4, 5).
Among several signaling approaches, one is autocrine where the signal is produced and accepted 
by the same cell. In case of juxtacrine signaling, the signal is only received by the adjacent cells 
through the cell membrane via membranous lipids and integral proteins. In addition to autocrine 
and juxtacrine, paracrine signaling involves signal transfer to the number of cells in its vicinity 
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and endocrine signaling deals with the target cells placed at 
a distance involving circulation through blood (6, 7). Several 
types of cancer cells, including breast carcinoma, communicate 
with each other as well as their neighboring cells via number 
of signaling pathways, including NF-κB (7, 8), Hedgehog (9), 
phosphatidylinositol 3-kinase-Akt (PI3K-Akt) (7, 10), Notch-
epidermal growth factor receptor (Notch-EGFR) (11), and 
short non-coding RNA export and import (12–14). The tumor 
microenvironment has a crucial part in the survival and growth 
of the cancer cells (15, 16).
The success or failure of these pathways is a key to regulate 
cell growth, proliferation, differentiation, apoptosis, and resist-
ance against genotoxic insults (17). Small non-coding RNAs are 
a group of highly conserved molecules responsible for controlling 
gene expression and dictating cellular signaling. microRNAs 
(miRNAs) as a type of short non-coding RNAs with a sequence of 
21–25 nt have widely been appreciated for their role in transcrip-
tional repression, mRNA degradation, and extra-environmental 
signaling (13, 18, 19). Recently, there are sufficient data pointing 
to upregulation and downregulation of miRNAs in setting up the 
platform for augmented pathophysiology of breast carcinoma 
(20). The concerted efforts of protein family cause the miRNA to 
be stabilized in the exterior region of the cells, making it accessible 
to get transported to local vicinity (13, 14, 19). Currently, signal-
ing pathways mediated by miRNAs have garnered wide attention 
in breast cancer pathophysiology. The abnormal exchange of 
signals involving non-coding short RNAs, including miRNAs, 
are found to create tumor-friendly microenvironment (21). One 
of the approaches to establish bridges between breast carcinoma 
and their microenvironment cellular community is exocytosis 
of tightly packed miRNAs (22–25). The current understanding 
and consensus have pointed out that distribution and expression 
of miRNAs are of utmost importance for disease prognosis and 
potential target in cancer therapy (26, 27).
In this review, we summarize biogenesis of miRNAs and their 
export mediated by exosome to target the neighboring cells in 
the microenvironment. The focus of this paper is to mark the 
miRNAs as a potent extracellular signaling molecule responsible 
for breast carcinoma pathophysiology.
CeLL SiGNALiNG OveRview 
iN BReAST TUMOR
Signaling is the key element for any cell to survive, grow, and 
proliferate. The mechanism of signaling is categorized into four 
types, autocrine, paracrine, juxtacrine, and endocrine signaling, 
which is described in the Section “Introduction.” Signaling path-
ways are based on the ligand–receptor binding complex, which 
leads to a much stronger downstream signal, thereby regulating 
the genetic expression. Signaling upon binding of a ligand in the 
cells mostly involves phosphorylation of the receptor at specific 
amino residues, which recruits various intracellular proteins 
amplifying the intensity toward the nucleus. There are a number 
of signaling pathways that are responsible for the cells growth, 
differentiation, proliferation, and also for resisting apoptosis and 
further metastasizing (28).
One of the signaling pathways is Notch pathway that is 
responsible for survival, growth, and proper development of cells. 
Notch is a transmembrane receptor, which has a strong affinity 
for the delta ligands and with its proteolytic cleavage travels 
to the nucleus and acts as transcriptional regulator activating 
gene expression. Some miRNAs either act as the notch receptor 
inhibitors or as the nuclear transcriptional inhibitors. As such, 
notch receptor inhibitor is miRNA-141, whereas Snail and zinc 
finger E-box binding homeobox 1 (ZEB1) transcriptional fac-
tors are inhibited by miRNA-34a (11). miRNA-374a is found 
to be overexpressed in Wnt/β-catenin pathway. For example, 
miRNA-451 acts as a potent inhibitor for the downstreaming 
signaling of the Wnt/β-catenin, decreasing the levels of β-catenin 
(29). Hedgehog is a developmental signaling pathway, which 
focuses on the embryogenesis, carcinogenesis, and tissue repair 
caused due to chronic inflammation. The oncogenic miRNA 
cluster family (miRNA17–92) regulates the Hedgehog signal-
ing (9). Signaling pathway NF-κB plays a crucial role in the 
cell proliferation, tumor development, inflammation, and also 
regulation of the innate and adaptive immune response (8). The 
pathway is also known to be guided by the expression of different 
miRNAs. There are several mechanisms by which NF-κB pathway 
is regulated. miRNA-21 targets signal transducer and activator of 
transcription 3 (STAT3), which is downregulated. Furthermore, 
miRNA-21 targets phosphatase and tensin homolog (PTEN), 
thereby inhibiting Akt phosphorylation and promoting NF-κB 
activation (30).
Cancer-associated fibroblasts are the stromal cells, non-
malignant in nature, which arise from the differentiation of the 
progenitor cells to promote tumor health by satisfying their 
nutrient needs (31, 32). Highly activated growth and proliferation 
of the cancer cells is due to unregulated signaling pathways. The 
tumor microenvironment helps the cancer cells for this aberrant 
signaling, as these cells are highly dependent on the microenvi-
ronment for their increased need of energy for their proliferation. 
This tumor microenvironment is solely responsible for causing 
apoptosis and drug resistance by cell–cell communication via 
some matrix soluble factors enhancing the cellular growth and its 
development (33). Overexpression of soluble growth factor such 
as cytokines, mediated by cancer-associated fibroblast cells, act-
ing as nutrient benefactor for the cells can decrease the integrin 
expression, further leading to metastatic progression (33).
TYPeS OF NON-CODiNG RNAs
Short non-coding RNAs consist of 1% of the genome (34), with 
size ranging from 20 to 25 nt. Small non-coding RNAs consist 
of miRNA, small interfering RNA (siRNA), piwi-interacting 
RNA (piRNA), small nucleolar RNA (snoRNA), and extracel-
lular RNA (exRNA) (35). These classes of short RNAs differ 
in the biogenesis and their mechanism of action (36). There is 
another category of non-coding RNA that is the long non-coding 
RNA (lncRNA). Short non-coding RNAs are directed by protein 
family, Argonaute (Ago), which guide the RNAs to their specific 
targets, thereby reducing the expression of the target gene (36). 
Among the class of non-coding RNA, miRNAs are known to 
Non-coding RNA
snoRNA
Long ncRNA
exRNA
scaRNA
piRNA
MicroRNA
siRNA snRNA
FiGURe 1 | Types of non-coding RNAs.
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play a pivotal role in the extracellular signaling of the cells. The 
flow diagram of different small non-coding RNAs is depicted 
in Figure 1.
Small interfering RNAs (siRNAs) are small (20–25 nt) double-
stranded RNAs that act through the RNA interference (RNAi) 
pathway to interfere with the expression of a specific gene 
containing a complementary sequence. RNAi can downregulate 
expression by inducing degradation of the targeted RNA, inter-
fering with transcription or inducing epigenetic changes to the 
gene (37).
Piwi-interacting RNAs also known as piRNA is a category of 
small non-coding RNAs with length slightly greater than miRNAs 
of about 26–31 nt. These categories of RNAs act as gene silencers. 
piRNA carries an anti-sense sequence to the transposons, thereby 
targeting the silencing of the transposons (38).
Small cajal body RNA (scaRNA) is an important player in the 
splicing mechanism, which regulates the spliceosome machinery 
by biochemically modifying specific nucleotide (39).
The extracellular miRNAs (exRNA) are one of the forms 
by which non-coding RNAs are exported. These exRNAs are 
loaded onto high-density lipids (HDLs) or bound by AGO2 
protein outside the donor cell, thereby protecting miRNA 
from RNA degrading enzymes. These are known to regulate 
cell–cell communication and are used as biomarkers in 
various diseases as these RNAs circulate stably in the blood 
stream (40, 41).
Small nucleolar RNA generally range from 60 to 300  nt in 
length and guide the site-specific modification of nucleotides 
in target RNAs via short regions of base pairing. There are two 
major classes, the box C/D snoRNAs, which guide 20-O-ribose-
methylation, and the box H/ACA snoRNAs, which guide 
pseudouridylation of target RNAs. These RNAs take part in the 
development of cancer, where they promote transformation, 
tumorigenesis, and metastasis (42).
Small nuclear RNA (snRNA) is one of the many small RNA 
species confined to the nucleus; several of the snRNAs are 
involved in splicing or other RNA processing reactions. The 
snRNAs are extremely conserved in both primary and second-
ary structure. Moreover, some residues seem to be completely 
invariant between organisms. They promote exon ligation and 
intron excision by acting as a catalyzing agent in the spliceosome 
machinery and thereby aiding the protein translation (43).
Long non-coding RNAs have received wide attention in gene 
regulation and are considered as non-protein coding transcripts 
longer than 200 nt. This nucleotide length limit differentiates long 
ncRNAs from small regulatory RNAs, such as miRNAs, short 
interfering RNAs (siRNAs), piRNAs, snoRNAs, and other short 
RNAs (44).
BiOGeNeSiS OF microRNA
First miRNA discovered was lin-4 of 22-nt length and was 
 identified in a gene responsible for postembryonic development 
in C. elegans carrying a complementary sequence in the 3′ UTR 
of  its regulatory target gene (34, 45, 46). There are about 6930 
miRNAs discovered in animals and their viruses (47). The miRNA 
gene is transcribed by RNA polymerase II to produce a primary 
microRNA (pri-miRNA) precursor molecule whose length varies 
greatly may be up to 3–4 kb (13, 19, 34, 45, 46). Furthermore, 
pri-miRNA undergoes nuclear cleavage with sequential actions 
by nuclear RNase III Drosha and a partner called DGCR8 with 
double-stranded RNA-binding domain forming a pre-miRNA, 
60–70 nt long, as a hairpin structure with two overhangs at their 
3′ and 5′ phosphate groups (34, 45, 46). Exportin-5 recognizes 
the 2-nt overhang generated by RNase III enzyme Drosha at the 
3′ end of pre-miRNA hairpin. The protein Exportin-5 (XPO5) 
plays a crucial role in escorting the pre-miRNA bound to Ran-
GTP from the nucleus to the cytoplasm through the nuclear pore 
(13, 19, 45). Cytoplasmic cleavage of the pre-miRNA occurs 
with cytoplasmic RNase III Dicer into ~22-nt miRNA duplexes. 
The Dicer, an endoribonuclease, interacts with the ends and 
cuts away the loop joining it, generating an imperfect duplex of 
miRNA:miRNA. In cytoplasm, the Dicer and TAR RNA-binding 
protein (TRBP) separates the two strands which are incorporated 
into the RNA-induced silencing complex (RISC), also known as 
miRISC (45). The strand with higher stability and the stronger 
base pairing is associated with the silencing complex and other 
proteins like Argonaute. The weaker strand in aspect of the two 
criteria can be either degraded or can act as a functional unit, 
further recruiting the RISC and protein complex (48).
The outline of miRNA biogenesis is illustrated in Figure  2. 
miRNA plays an important role in the posttranscriptional regula-
tion by recognizing the specific mRNA and incompletely pairing 
with the 3′ untranslated region causing translational suppression 
and inhibition of protein synthesis or by degrading the mRNA. 
They play a major role in making diverse biological decisions 
such as proliferation, differentiation, and apoptosis. miRNA 
can be secreted as circulating miRNA (49) that can either exist 
outside the cells with the help of various binding proteins or can 
be exported outside by extracellular vesicles such as exosomes, 
microvesicles, or apoptotic bodies (50). RNA-binding protein 
(RBP), Ago-1, and high-density lipopolysaccharides have been 
reported to assist miRNA out of the cells and prevent its degrada-
tion. miRNAs present in the blood plasma are most stable in the 
microenvironment carrying the property of resisting high and 
low temperature and varied pH (40). Among all the non-coding 
RNAs, only miRNAs are seen to play a pivotal role in tumor 
signaling and also in cardiovascular, neurological, and other 
developmental diseases (51, 52).
FiGURe 2 | This illustration depicts the miRNA biogenesis. This represents the canonical maturation where primary miRNA transcripts (pre-miRNAs) 
are generated by RNA polymerase ii or iii and cleavage of the pre-miRNAs by the microprocessor complex Drosha–DGCR8 (Pasha) in the nucleus. 
The pre-miRNAs exit from the nucleus to the cytoplasm by exportin 5 (XPO5). In the cytoplasm, it is further processed by DICER1, a ribonuclease III (RIII) 
enzyme, that gives rise to the mature miRNAs. One strand of the mature miRNA (the guide strand) is loaded into the miRNA-induced silencing complex (miRISC) 
comprising DICER1 and Argonaute (AGO) proteins. The binding of miRNA to target mRNAs is facilitated by sequence complementary binding, leading to 
translational repression. This schematic diagram is modified from Lin and Gregory (42).
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PACKAGiNG AND SHiPPiNG OF miRNAs
microRNAs are protected from the potent degrading factors 
such as RNase during circulation and signaling through the 
microenvironment. The diagram showing mode of miRNA 
export is provided in Figure 3. These miRNAs are shielded by 
two ways, one being encapsulation in the extracellular vesicles, 
namely, exosomes, microvesicles, or apoptotic bodies (53) and 
the other being complexing with number of RBPs, such as Ago 
protein family, or HDL, that occurs in the blood plasma (54). All 
the three categories of the extracellular vesicles share the same 
membrane composition, thereby making it tedious to separate 
out, but they carry different pathways of biogenesis and secretary 
mechanism (55).
Exosomes are lipid vesicles ranging between 40 and 100 nm in 
diameters, which arise from the inward budding of plasma mem-
brane of the cell forming an intraluminal vesicle (56). They are 
associated with the plasma membrane through ligand–receptor 
interactions (57, 58) or lipids. Exosomes carry a property of taking 
up various miRNAs, mRNAs, and proteins without eliciting any 
immune response (59). These vesicles are relatively stable in the 
cell’s external environment and can easily cross the blood–brain 
barrier. Exosomes are composed of numerous protein families 
such as tetraspanin proteins, CD63, CD9, and CD81. Primarily, 
the cell membrane is internalized to form an endosome, fol-
lowed by the formation of small vesicles inside the endosomes. 
These endosomes are then called multivesicular bodies, and 
they transfer the vesicles into the extracellular space in the form 
of exosomes (60). The exosome membrane contains lipid rafts 
containing cholesterol, sphingolipids, glycerophospholipids, and 
ceramide. The protein content is also significant for the vesicle 
to travel and target the cell membrane. Various proteins, such as 
integrin family, cytoskeletal proteins, heat-shock protein family, 
and vesicle trafficking proteins, play a role in making the vesicular 
environment habitual for shipping the RNAs and proteins (61).
The levels of signaling via exosomes or vesicular transport 
have seen to be elevated in tumor cells as compared with the 
normal cells. There are lots of compounds which are studied to 
act on a target molecule to inhibit the formation of the extracel-
lular vesicles carriers, thereby creating a signaling gap within 
the tumor microenvironment. Molecules, such as proton pump 
inhibitors, methyl-β-cyclodextrin, and annexin, are known to 
inhibit the vesicle formation by targeting the Na+ reabsorption, 
cholesterol, and phosphatidylserine, respectively, and thereby 
blocking the membrane fusion, lipid raft-mediated endocytosis, 
and phagocytosis (62).
Microvesicles also referred as shedding microvesicles or 
ectosomes are small membranous sacs, which are the product 
of the budding and blebbing of plasma membrane (56, 63). 
Microvesicles are large vesicles, which are 50–1000 nm in diam-
eter. Microvesicles participate in the cells growth, proliferation, 
and its death. There are tumor-originated microvesicles, which 
are secreted into the tumor microenvironment, which helps the 
neighboring cells to secrete cytokines, which can help the tumor 
replenish and can mask the immune response (64).
Apoptotic bodies also called apo-bodies arise from the cells 
undergoing cell death by apoptosis. These are the largest of the 
extracellular vesicles of 400–4000 nm in diameter. These bodies 
consist of the condensed chromatin and cytoskeletal proteins 
(65). As these arise from the shrinkage of the cell, there are many 
FiGURe 3 | This figure describes the modes of miRNA export to neighboring cells. The miRNAs are being exported out of the donor cells with the 
help of various carriers, membrane-derived vesicles (exosomes, microvesicles, apoptotic bodies), miRNA-binding protein complexes (RBPs), or 
high-density lipoproteins (HDL).  Finally, miRNAs entered to recipient cells where they are engaged in gene expression alterations. This illustration is modified 
from Thery (55) and Crescitelli et al. (53).
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RNA and DNA fragments present whose uptake can result into 
the transcriptional repression (66).
Extracellular miRNAs are associated with lipid-based carriers 
and lipid-free proteins (62). Circulating miRNAs are stable when 
they are associated with plasma, which serves as the disease bio-
markers (67). The miRNA-223 is found to be transported using 
HDL molecule, and the Ago protein family is associated with the 
extracellular miRNA transport accompanying both in and out of 
the cell (67). Exosome circulate for a short time in the body fluids 
before getting internalized into the recipient cell, a process called 
free floating. Furthermore, adhesion requires a conformational 
change in the status of the low affinity to high affinity binding to 
integrin-bound exosome (68). Uptake of exosome is dependent 
upon the signaling status of the recipient cell and the protein 
composition of the vesicle (69). Exosome internalization involves 
various mechanisms such as membrane fusion, soluble signaling, 
juxtacrine signaling, lipid raft-mediated endocytosis, and macro-
pinocytosis (68). These mechanisms are either receptor-based 
or involve actin filament protrusions, which engulf the vesicle 
dispatching the cargo in the cytoplasm (70).
Release of exosomes or microvesicles occurs in the similar 
fashion like the viral budding (63, 71). The property of the plasma 
membrane forming a protrusion is driven by a number of proteins 
and lipids associated with the membrane. The budding of the 
exosomes via endocytosis and membrane trafficking is mediated 
via various coat proteins like clathrins and others like annexing, 
a Ca2+ binding protein, which are present in the cell and which 
has the ability to recruit phosphatidylinositol 4,5-bisphosphate 
[PI(4,5)P2], sphingolipids, and cholesterol (72). A protein motif 
called amphipathic helix that acts on the integral site and mem-
brane proteins that bind on the periphery senses the membrane 
curvatures and are inserted into the membrane, facilitating the 
budding, and thereby the vesicle formation (69). Lipid rafts play 
a major role in the promotion of signaling mediated through 
proteins anchored by glycophosphatidylinositol and help in sort-
ing and membrane trafficking in the secretory pathways (62, 73).
COMMUNiCATiON BRiDGe BeTweeN 
miRNAs TO NeiGHBORiNG FiBROBLAST
Specific targeted therapies can be achieved by encapsulating the 
drug into the exosomes with a clear prospect of the therapeutic 
cargo, the peptide or DNA target of the drug, mode of uptake, and 
mechanism of their action (74). Some miRNA-targeted therapies 
are also being designed to deliver antitumor miRNA to the 
breast tumor cells (75). Exosomes have natural ability to transfer 
genetic material both locally and systemically, and, therefore, 
many research groups investigated these vesicles as therapeutic 
agents. As an instance, microvesicles isolated from endothelial 
progenitor cells (EPCs) contained proangiogenic miRNA-126 
and miRNA-296 (76), and transfer of these miRNAs triggered the 
activation of the PI3K/Akt signaling pathway and phosphoryla-
tion of endothelial nitric oxide synthases and directed endothelial 
cells to undergo angiogenic and antiapoptotic program (77).
The pivotal role played by the microenvironment-associated 
resident cells in breast tumor progression has been widely appre-
ciated. In a recent attempt to emphasize the give and take type of 
exosome-based connection between breast carcinoma and pread-
ipocyte, a type of cellular community in the tumor microenviron-
ment has been reported with clear role of miR-140/SOX2/SOX9 
axis that may regulate tumor microenvironment signaling and 
communication (78). Intentionally diverted glucose metabolisms 
are a trademark of breast carcinoma. In recent findings, several 
research groups have attempted to provide evidence that breast 
carcinoma cells use the secreted vesicle-contained miRNAs as a 
tool to deprive of the neighboring cells for their food availability, 
in particular, they target the glucose uptake (79). They have also 
convincingly mentioned that breast carcinoma may use such 
FiGURe 4 | enhancement of interaction by miRNAs bridge breast tumor and their microenvironment.
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strategy to reprogram and progress with destructive metastasis 
goal (80).
As an evidence of influencing the progression of breast phyl-
lodes tumor xenografts, miRNA-21 enhanced tumor growth 
and facilitated metastasis by inducing myofibroblast differentia-
tion (81). The recurrence and relapse of breast carcinoma after 
removal of primary tumor may be driven by well-communicated 
cell–cell signaling, leading to cancer cell dormancy. In view of the 
role of secreted miRNAs in maintaining the dormancy of breast 
cancer cells, evidence has explained that exosomal transfer of 
miRNA-23b from the bone marrow may promote breast cancer 
cell dormancy in metastatic settings (82). Such observation 
will lead to insights for therapeutic approaches by blocking the 
miRNA-23b-mediated dormancy control in breast cancer cells so 
that further cell cycling stages of cancer cells will succumb to the 
drug regimen therapy (82).
The differential expressions of miRNAs in the context of 
contribution of cancer-associated fibroblast in breast cancer pro-
gression are being unraveled. In the same line, the experimental 
evidence points out that miRNA-26b is highly aberrant miRNAs 
found in cancer-associated fibroblast and may be implicated in 
breast carcinoma progression, growth, and recurrence (83).
There is growing view that the cancer-associated fibroblasts 
and normal fibroblasts being in the neighborhood of breast tumor 
act differently with the first responsible for inducing breast tumor 
progression and second engaged in tumor blockade. In  this 
context, about 11 dysregulated miRNAs in cancer-associated 
fibroblasts have been pinpointed that include three upregulated 
(miRNA-221-5p, miRNA-31-3p, and miRNA-221-3p) and 
eight downregulated (miRNA-205, miRNA-200b, miRNA-200c, 
miRNA-141, miRNA-101, miRNA-342-3p, let-7g, and miRNA-
26b) (84). Furthermore, such observation accentuates the notion 
that miRNAs derived from breast tumor neighboring cells may 
influence the status of breast tumor through cell–cell commu-
nication (85).
The collaboration between stromal cell community and 
breast tumor cell is being overwhelmingly recognized as a fac-
tor behind the tumor progression and development. In recent 
evidence, there are highlighted reports that suggest that the 
miRNA-320 is a vital component of the phosphatase and tensin 
homolog deleted on chromosome 10 (Pten) tumor suppressor 
axis that works in stromal fibroblasts to manipulate the tumor 
microenvironment and restrain tumor progression (86). The 
inducement of senescence has been considered as a blockade 
for different cancer cell progression, including breast carcinoma. 
There has been report on the contribution in tumor suppression 
by senescence-associated microRNAs (SA-miRNAs), miRNA-22, 
which is overexpressed in human senescent fibroblasts and 
epithelial cells. Since, such reports validate the idea of commu-
nication bridge between stromal cell and tumor cell progression, 
further studies will provide better understanding and platform 
for therapy approaches by manipulating the miRNA level in the 
tumor neighborhood cell community (87).
The Communication Bridge between 
Carcinoma and Surrounding Macrophage
In an effort to delineate the collaboration between breast 
carcinoma and their cellular community in microenvironment, 
authors have reported that miRNA-21 and miRNA-29a expres-
sion are upregulated in tumor-infiltrated myeloid cells and 
macrophages. Furthermore, authors have suggested that these 
upregulated miRNAs act as helping hand for the breast tumor for 
their progression and metastasis (88). In recent time, there are 
emerging evidence of close association between breast carcinoma 
TABLe 1 | The summary of oncogenic microRNAs reported in literature.
Oncogenic 
miRNAs 
(OncomiRNAs)
Function in breast cancer when 
overexpressed
Reference
miRNA-10b Decreases E-cadherin level leading to 
metastasis
(99, 100)
Silences tumor suppressor homeoboxD10 
(HOXD10) pathway
miRNA-373 Downregulates CD44 causes migration (8, 101, 102)
Makes the cell resistant to apoptosis
Promotes cell growth, migration, and invasion
miRNA-21 Targets PDCD4 and HIF1A gene causing 
increased cell growth, invasion, and EMT
(103)
miRNA-155 Downregulates FOXO3A gene which causes 
chemotherapy resistance and reoccurrence 
of tumor
(104)
TABLe 2 | The summary of tumor suppressor miRNAs reported in 
literature.
Tumor 
suppressor 
miRNAs
Function in breast cancer Reference
miRNA 17–92 
family
Regulates TGF-β pathway by targeting TGF-β 
receptor II and the Smad 2 and Smad 4 
proteins
(105, 106)
Targets Mekk2/Mek5/Erk5 pathway enhancing 
the recognition of NK cells for the tumors
miRNA 125b Targets erbB2/erbB3 causing decrease in 
cell proliferation, differentiation, and induce 
apoptosis
(107)
miRNA 200 Targets transcriptional repressors ZEB and 
upregulate the E-cadherin level inhibiting the 
epithelial to mesenchymal transition (EMT) and 
cell proliferation
(20, 84)
miRNA-146b Targets STAT3 and NF-kB signaling pathway (108, 109)
TABLe 3 | List of miRNAs and their status on clinical trails.
miRNAs Details of clinical trails Reference
microRNA miR-
RX34 (MRX34)
A multicenter phase I study of MRX34, 
microRNA miR-RX34 to evaluate the safety of 
MRX34 in patients with primary liver cancer 
or other selected solid tumors or hematologic 
malignancies
(26, 27, 10)
miRNAs panel The use of a miRNAs panel to identify thyroid 
malignancy in FNA leftover cells and the effect 
of these miRNAs on target genes
(111)
miRNA 200 microRNAs (miRNAs) consisting of 6 miRNA 
(miRNA-21, miRNA-20a–5p, miRNA-103a–3p,  
miRNA-106b–5p, miRNA-143–5p, and 
miRNA-215) was found effective to identify 
whether one should accept adjuvant 
chemotherapy or not
(112)
miRNAs panel Plasma microRNA profiling as first line 
screening test for lung cancer detection: a 
prospective study
(113)
miRNAs panel A perspective study of the predictive value 
of microRNA in patients with HER2 positive 
advanced stage breast cancer who were 
treated with herceptin
(114)
miRNA-29b The role of microRNA-29b in the oral 
squamous cell carcinoma
(115)
Circulating 
miRNAs
Circulating miRNAs: novel breast cancer 
biomarkers and their use for guiding and 
monitoring response to chemotherapy
(116)
miRNA-10b Evaluating the expression levels of microRNA-
10b in patients with gliomas
(117)
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and carcinoma-trained or -taught macrophages, in tumor 
microenvironment. Furthermore, the miRNA profiling data cor-
roborated the observation that deregulated miRNAs expression 
level is linked with breast tumor progression and prognosis (89). 
Recent convincing view is that breast tumor-associated mac-
rophages are being extensively causative in the trademark settings 
of tumor microenvironment. To understand such phenomena, 
one study suggested that a crucial extra player, miRNA-19a-3p, 
highly expressed in tumor-associated macrophages may be able 
to retard breast cancer progression and metastasis through the 
downregulation of Fra-1 proto-oncogene (90).
The friendly promotion of breast cancer progression and 
metastasis by tumor-associated macrophages has extensively 
been highlighted in recent times. In the same direction, there 
are reports on macrophage-secreted exosome-encapsulating 
miRNAs such as miRNA-223 that are packed to deliver breast 
carcinoma and upon entry into the cancer cells resulted into 
better potentiation of carcinoma cells for their progression and 
metastasis (91). Recently, appreciation has been received to find 
the clue behind friendly neighborhood cell community in sup-
porting the survival strategy of breast carcinoma cells.
Crosstalk between Carcinoma and 
Stromal Cells
In the line of reported macrophages, fibroblast, and epithelial 
cells, there are findings on the contribution of human mesen-
chymal stem/stromal cells (hMSCs) to upkeep breast cancer 
survival advantages mediated by the secretome. Furthermore, 
Vallabhaneni et al. (92) have also demonstrated and characterized 
the role of miRNA-21 and 34a as tumor-friendly miRNAs. Being 
heterogeneous within the breast tumor milieu, the breast cancer 
cells are always receptive toward any signals or messages coming 
from the outside stromal cells populations. To investigate such 
cell–cell crosstalk, the facts have established that communica-
tion between stromal stem cells with the breast carcinoma cells 
mediated by Twist1 protein player leads to aberrant expression 
of miRNAs, specifically led by miRNA-199a, which ultimately 
landed in repression of Forkhead box protein P2 (FOXP2) 
transcription factor, that may be responsible to encourage breast 
cancer survival and progression (93).
There has been interest in the clues or signals contributing 
to molecular alterations in breast tumor stromal environment 
that actually contribute in the betterment of breast carcinoma. 
To follow such unrevealed, it was pointed out that upregulation 
of miRNA-21 in stromal cells may be helping breast tumor for 
progression and linked it as a prognostic factor (94). The release 
of extracellular vesicular cargo containing vital messenger in the 
form of proteins, miRNAs, or tRNAs has been reported from both 
breast carcinoma and their neighborhood cells, and such cargo 
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gifs are released in the microenvironment to guide or mentor each 
other type of cells (95). In future, better understanding of molecu-
lar interplay involved in the breast tumor microenvironment sup-
porting the breast tumor progression and metastasis may open up 
the therapeutic intervention strategy or early detection (95, 96).
The contributions of stromal cells in the breast tumor 
progression are being established through multiple molecular 
mechanisms, such as augmented invasiveness, angiogenesis, and 
immunosurveillance masking. The recent experimental data 
report that miRNA-126/miRNA-126(pair) overwhelms the 
sequential recruitment of mesenchymal stem cells and inflam-
matory monocytes into the tumor stroma, leading to the breast 
tumor metastasis. In other words, downregulation of miRNA-
126/miRNA-126(pair) in the breast carcinoma cells may be a 
strategy to avoid immunosurveillance in tumor (97) and more 
such examples are depicted in the Figure 4.
The Summary of Therapeutic Relevant 
miRNAs
Oncogenic microRNAs (OncomiRNAs) dysregulation causes 
the onset of cancer. OncomiRs act as negative regulators of the 
tumor suppressor genes. The most screened miRNAs as prog-
nostic markers of breast cancers are miRNA-10b, miRNA-21, 
miRNA-373, and miRNA-27a (20, 98). The summarized reviews 
on oncogenic miRNAs are presented in Table 1.
Tumor Suppressor miRNAs
Tumor progression can lead to increase and decrease of some 
exosome-mediated miRNAs. The decreased miRNAs are known 
to play a role as suppressor of the tumor. These miRNAs inhibit 
the growth of tumor by negatively regulating the OncomiRNAs 
(15, 26, 27). In wide prospects as oncogenic, tumor suppressor, 
prognosis, and diagnosis tools in cancer, there are appreciable 
efforts that have been reported in the form of clinical trails, and 
few examples have been listed in Tables 2 and 3.
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ReFeReNCeS
1. Stewart BWKP, Wild CP. World Cancer Report 2014. (2015). Lyon CEDEX, 
France.
2. Drabsch Y, Ten Dijke P. TGF-β signalling and its role in cancer progression 
and metastasis. Cancer Metastasis Rev (2012) 31:553–68. doi:10.1007/
s10555-012-9375-7 
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortettieulent J, Jemal A. Global cancer 
statistics, 2012. CA Cancer J Clin (2015) 65:87–108. doi:10.3322/caac.21262 
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug 
resistance: an evolving paradigm. Nat Rev Cancer (2013) 13:714–26. 
doi:10.1038/nrc3599 
5. Timp W, Feinberg A. Cancer as a dysregulated epigenome allowing cel-
lular growth advantage at the expense of the host. Nat Rev Cancer (2013) 
13:497–510. doi:10.1038/nrc3486 
6. Cheung KJ, Ewald A. Illuminating breast cancer invasion: diverse roles for 
cell-cell interactions. Curr Opin Cell Biol (2014) 30:99–111. doi:10.1016/j.
ceb.2014.07.003 
7. Kolch W, Halasz M, Granovskaya M, Kholodenko BN. The dynamic control 
of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 
15(9):515–27. doi:10.1038/nrc3983 
8. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, 
Shavinskaya A, et  al. microRNA-520/373 family functions as a tumor 
suppressor in estrogen receptor negative breast cancer by targeting NF-κB 
and TGF-β signaling pathways. Oncogene (2012) 31:4150–63. doi:10.1038/
onc.2011.571 
9. Jia Y, Wang Y, Xie J. The Hedgehog pathway: role in cell differentiation, 
polarity and proliferation. Arch Toxicol (2015) 89:179–91. doi:10.1007/
s00204-014-1433-1 
10. Fruman D, Christian R. PI3K and cancer: lessons, challenges and opportuni-
ties. Nat Rev Drug Discov (2014) 13:140–56. doi:10.1038/nrd4204 
11. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: 
clinical development advances and challenges. Pharmacol Ther (2014) 
141:140–9. doi:10.1016/j.pharmthera.2013.09.005 
12. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and 
friends. J Cell Biol (2013) 200:373–83. doi:10.1083/jcb.201211138 
of cancer, including breast carcinoma. Decades of research has 
provided in-depth information regarding the non-coding RNA 
pathways. miRNAs are known for their ability to communicate 
with the extracellular microenvironment comprising of cells in 
its proximity via vesicle-derived cargo or conjugated proteins. 
Levels of various miRNAs differ according to the progression 
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